Edward Haeggström
CEO, Nanoform
In 2015, Haeggström commercialized the nanoparticle engineering platform he developed with Jouko Yliruusi, acting professor at the University of Helsinki, Finland. This marked the beginning of Nanoform. When asked about what could improve the pharma industry, he responded, “The shift toward a more patient-centric approach in the design of new drugs is something that has been gaining momentum and which I am keen to see more of in the pharma industry. It is my belief that it is not only patients who stand to gain from therapies more tailored to their needs, but also a chance for pharma to grow from both a commercial and humanitarian standpoint. Wider adoption of patient-centric practices and incorporation of patients’ feedback from the early stages of drug discovery through to development has the potential to revolutionize patients’ quality of life. In today’s ever more technologically advanced world, it is easier than ever to achieve.”
